BeiGene
BeiGene is a global biotechnology company focused on developing innovative oncology medicines, with a workforce of over 10,000 employees and operations in 40 countries across five continents.
Services
BeiGene is committed to bringing patients worldwide better treatment options through clinical trials. The company manufactures and markets key oncology medicines such as BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab), and Pamiparib (BGB-290). It also offers a Patient Support Program and Expanded Access Programs to facilitate patient care and accessibility to treatments. Additionally, BeiGene collaborates with various biopharmaceutical companies, including Amgen, Bristol Myers Squibb for Celgene, and Novartis.
Global Operations
BeiGene operates in 40 countries across five continents, boasting a global workforce of over 10,000 employees. The company has a significant presence in Asia, Australia, Europe, Latin America, and North America. It is headquartered in Basel, Beijing, and Cambridge, Mass., and is traded on three major stock exchanges: the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.
Products
BeiGene's product portfolio includes notable oncology medicines such as BRUKINSA, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), and TEVIMBRA, a humanized monoclonal antibody targeting the immune checkpoint receptor PD-1. BRUKINSA is approved for treating various B-cell malignancies in 70 markets worldwide, while TEVIMBRA is approved for managing various solid tumors globally. The company also produces and markets Pamiparib (BGB-290), targeting different cancer types.
Research and Clinical Trials
BeiGene is known for its innovative oncology research, with one of the world’s largest oncology research teams. It focuses on recruiting diverse clinical trials across a broad range of therapeutic indications, including lymphoma, liver cancers, lung cancers, gastric cancers, and breast cancers. The company has a broad and deep pipeline aiming to address 80% of the world’s cancers by type and is committed to responsible business practices and sustainability in its research efforts.
Recognition and Achievements
BeiGene's commitment to innovation and impact in the oncology field has earned it recognition. In 2024, it was named one of Fast Company’s World’s Most Innovative Companies. The company's responsible business practices, dedicated BeiGene Foundation, and provision of Independent Medical Education Grants underscore its commitment to advancing medical knowledge and supporting global health outcomes.